
Lyudmila Bazhenova, MD, explains why the updated taletrectinib label does not change her practice and reviews new WCLC subgroup data in ROS1+ NSCLC.
A 60-Year Old Man With Untreated Stage IV EGFR-Mutated Non-Small Cell Lung Cancer
Case: A 60-Year-Old Male with Untreated Stage IVEGFR+NSCLC
Initial presentation
Clinical workup
Treatment
Stay up to date on practice-changing data in community practice.
Subscribe


